New hope for nigerian women with aggressive breast cancer: targeted therapy trial underway
NCT ID NCT03879577
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 2 trial is testing a combination of two drugs—docetaxel (chemotherapy) and trastuzumab (a targeted therapy)—in 53 Nigerian women with HER2-positive breast cancer. The goal is to see how many women have no cancer left after treatment (called a complete response). The study also tracks side effects and how long women stay cancer-free. All participants are treated at a single center in Nigeria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Docetaxel and trastuzumab (Herceptin), with possible FEC, tamoxifen, or letrozole
What this could lead to
If successful, this could show that a standard chemotherapy plus targeted therapy regimen works well in Nigerian women with HER2-positive breast cancer, potentially improving treatment options in this population.
What could go wrong
This is a small, single-arm Phase 2 study with only 53 participants, so results may not apply broadly. Side effects from chemotherapy and trastuzumab can be serious, including heart problems and infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
University College Hospital, Ibadan, Nigeria
Ibadan, Nigeria